Krystal Biotech’s Gene Therapy Expansion: Promising Preclinical Results and Long-term Value Proposition

In a report released today, Joseph Pantginis from H.C. Wainwright reiterated a Buy rating on Krystal Biotech (KRYS – Research Report), with a price target of $240.00.

Joseph Pantginis has given his Buy rating due to a combination of factors including the expansion of Krystal Biotech’s gene therapy platform with the addition of KB111 and KB112. These new therapies target rare skin diseases, Hailey-Hailey and Darier diseases, which are caused by specific genetic mutations. The preclinical data presented at the Society for Investigative Dermatology 2025 Annual Meeting showed promising results, indicating that both KB111 and KB112 can effectively transduce keratinocytes and express the necessary proteins with minimal toxicity.
Furthermore, the successful development of these therapies underscores the potential of Krystal’s HSV-1-based platform, which has already seen success with the FDA and EMA approved VYJUVEK for B-VEC. This expansion not only validates the platform’s versatility but also enhances the company’s long-term value proposition. Pantginis’s confidence in Krystal Biotech’s innovative approach and its ability to address unmet medical needs in rare skin disorders is reflected in his Buy rating.

Pantginis covers the Healthcare sector, focusing on stocks such as Cytokinetics, Actinium Pharmaceuticals, and Viking Therapeutics. According to TipRanks, Pantginis has an average return of -22.1% and a 24.47% success rate on recommended stocks.

In another report released yesterday, Evercore ISI also maintained a Buy rating on the stock with a $200.00 price target.